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Abstract
For in vitro studies of airway pathophysiology, primary epithelial cells have many advantages over immortalised cell lines.
Nasal epithelial cells are easier to obtain than bronchial epithelial cells and can be used as an alternative for in vitro studies.
Our objective was to compare nasal and bronchial epithelial cells from subjects with COPD to establish if these cells respond
similarly to pro-inflammatory stimuli. Cell cultures from paired nasal and bronchial brushings (21 subjects) were incubated
with cigarette smoke extract (CSE) prior to stimulation with Pseudomonas aeruginosa lipopolysaccharide. IL-6 and IL-8 were
measured by ELISA and Toll-like receptor 4 (TLR-4) message and expression by RT-PCR and FACS respectively. IL-8 release
correlated significantly between the two cell types. IL-6 secretion was significantly less from bronchial compared to nasal
epithelial cells and secreted concentrations did not correlate. A 4 h CSE incubation was immunosuppressive for both nasal
and bronchial cells, however prolonged incubation for 24 h was pro-inflammatory solely for the nasal cells. CSE reduced
TLR-4 expression in bronchial cells only after 24 h, and was without effect on mRNA expression. In subjects with COPD, nasal
epithelial cells cannot substitute for in vitro bronchial epithelial cells in airway inflammation studies.
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Introduction
The airway epithelium is a vital part of our immune defences
against pathogens, allergens and other noxious agents such as
cigarette smoke. Airway epithelial cells have the ability to
synthesise and secrete cytokines, chemokines, and anti-microbial
substances. Profound differences in the constitutive and stimulated
expression and secretion of IL-8 by airway epithelial cells from
healthy volunteers and patients with chronic obstructive pulmo-
nary disease (COPD) have been described [1].
There is an increasing body of research dedicated to the study of
primary epithelial cells from patients with asthma [2] and cystic
fibrosis [3], with fewer studies examining epithelial cells from
patients with COPD [1,4]. Airway epithelial cells have usually
been obtained from transplant lungs or surgical specimens, but the
use of nasal or bronchial brushings has now become increasingly
popular [3,5,6]. Nasal brushings are less invasive, more acceptable
for patients and easier to perform than bronchial brushings.
However, few studies have directly compared data from nasal and
bronchial brushings. McDougall –et al. reported that nasal cells
could be used as surrogates for bronchial cells in studies of airway
inflammation [6]. Furthermore, MacRedmond –et al. demonstrat-
ed a strong correlation in TLR-4 mRNA expression from cells
obtained from the upper and lower respiratory tract, both
obtained by brush sampling, in a group of COPD patients [5].
In contrast, Thavagnanam and co-workers found differences
between nasal and bronchial epithelial cells from subjects with and
without asthma under basal conditions and after IL-13 treatment
[7].
There is increasing evidence that the disease process in COPD
is not confined to the lower airways. Sinonasal symptoms in
COPD have been reported ranging from 75% [8] to as much as
88% [9]. These findings highlight that the pathophysiology of
COPD is not merely confined to the lower airways. This is not
particularly surprising, as although smokers may vary in terms of
the frequency and depth of inhalation of cigarette smoke, for many
of these individuals the entire airway is exposed to volatile cigarette
smoke.
To investigate the action of cigarette smoke extract (CSE) on
epithelial cells, we compared the responses of paired nasal and
bronchial epithelial cells obtained from patients with COPD. We
hypothesised that nasal and bronchial epithelial cells, obtained by
brushings at each site, demonstrate similar release of IL-8 and IL-6
after LPS stimulation.
Materials and Methods
Study Subjects
Patients with a diagnosis of mild COPD according to the British
Thoracic Society guidelines were included [10]. All subjects
required an elective bronchoscopy as part of their clinical
investigation. Subjects with bronchiectasis, a clinical diagnosis of
lung carcinoma, or other significant pulmonary or nasal pathology
were excluded. This study was approved by the Office for
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provided written informed consent (REC: 09/NIR03/42).
Nasal and bronchial brushings
Bilateral nasal brushings were performed using a bronchial
cytology brush (TeleMed Systems Inc., MA, USA) from the medial
aspect of the inferior turbinate as previously described [11].
During bronchoscopy, four bronchial brushings in the third
generation bronchus were obtained. Nasal and bronchial cells
were then expanded in bronchial epithelial growth medium
(BEGM, Promocell, Germany) [11].
Cells (passage 2–3; 6610
4 cells per well) were seeded in purified
bovine collagen coated (PureCol; Advanced Biomatrix) 12–well
plates and cultured for 24 h. Cells were stimulated with LPS from
Pseudomonas aeruginosa (Sigma-Aldrich) either with or without CSE
pretreatment for 4 h or 24 h as outlined in the results section.
Separate cultures were treated with acrolein (up to 30 mM for 4 h).
Media were collected for the determination of cytokine produc-
tion, and cells were used for mRNA or protein expression studies.
After appropriate stimulation, cell–free supernatants were col-
lected and stored at 220u for future IL-8 and IL-6 measurement
using the Duoset ELISA kits (R&D Systems) according to the
manufacturer’s instructions.
For experiments in air-liquid interface (ALI) cultures, cells were
seeded onto collagen coated Transwells (Corning Inc, USA) at a
seeding density of 1.5610
5 cells per well and grown until cultures
became confluent and developed tight junctions. At this stage the
apical media was removed and the cell cultures fed basolaterally
only on alternate days for 28 days. Mucus secretion was apparent
after approximately 14 days in culture.
Immunofluorescence
Cells were seeded on coverslips at a density of 1610
5 cells/ml.
The following day, cells were fixed in 4% PFA and washed in PBS.
After permeabilisation with 0.2% Triton-X 100 (Sigma, Dorset,
UK), cells were treated with a 1:100 dilution of rabbit anti-
cytokeratin-5 primary antibody (Abcam, Cambridge, UK) over-
night at 4uC. The primary antibody was detected using a 1:500
dilution of Alexafluor 568 goat anti-rabbit IgG (Invitrogen Ltd.,
Paisley, UK). Nuclei were stained with DAPI (Vector Laborato-
ries, Peterborough, UK). Images were captured using LAS AF
(Leica) acquisition software.
Cigarette smoke extract preparation
CSE was prepared by a modification of the method of Richter
et al. [12] Briefly, one Marlboro cigarette (0.8 mg nicotine; 10 mg
Tar; 10 mg carbon monoxide) was combusted with a modified
syringe-driven apparatus. The smoke was bubbled through 25 ml
of media over 5 minutes by drawing 35-ml volume of smoke every
15 s. The resulting suspension was filtered through a 0.2 mm pore-
size filter to remove large particles and bacteria. This solution was
regarded as ‘‘100% CSE’’ and was freshly generated for each
experiment, and subsequently diluted with culture medium to
obtain a final 5% working concentration. CSE was used
immediately to avoid break-down or evaporation of components.
The optical density of CSE measured at 450 nm did not vary
significantly when comparing a series of 5% CSE preparations
(OD approx. 0.25).
FACS analysis
Cell surface expression of TLR-4 was determined by FACS
analysis. In brief, cells were detached from wells by incubating
with cell dissociation fluid (Sigma-Aldrich) in PBS at 37uC. For the
analysis of intracellular TLR-4, cells were permeabilised and fixed
by incubating them with fixation and permeabilization buffer
(eBioscience, USA) as per supplier’s instructions and then washed
twice with staining solution containing 1.0% BSA and 0.02%
sodium azide in PBS. Cells, adjusted to 1610
5 cells per 100 mli n
PBS/1% BSA, were subsequently stained in darkness for 30 min
at 4uC with phycoerthrin (PE)-conjugated anti-TLR-4 monoclonal
antibodies or PE-mouse isotype control (eBioscience, USA).
Analysis of 10,000 events was performed using an Epics XL flow
cytometer (Beckman Coulter, UK Ltd). Cells were initially gated
on the basis of forward and side scatter characteristics. Results are
expressed as relative mean fluorescence intensity (rMFI =
monoclonal antibody/corresponding isotype control) as no
bimodal distribution was found.
RT- PCR Analysis of TLR-4 mRNA
RNA was isolated using the RNeasy Mini kit (Qiagen, UK).
RNA quality and quantity were evaluated by UV spectropho-
tometry. cDNA was prepared by first-strand cDNA synthesis from
1 mg total RNA using Roche first strand cDNA synthesis kit for
RT-PCR according to manufacturer’s instructions (First strand
cDNA synthesis Kit, Roche). For PCR quantification, 1 mlo f
cDNA reaction were amplified in a 10 ml standard PCR in a
thermo-Fast 96-well detection plate and run on the spectrofluo-
rometric thermal cycler AB 1200. PCR for GAPDH and TLR-4
were performed in parallel. The threshold cycle number (Ct) for
each sample was determined. The gene-specific Ct for each
sample was corrected by subtracting the Ct for the house-keeping
GAPDH (DCt). Untreated samples were chosen as the reference
samples and their DCt values were subtracted to the DCt from the
treated samples to obtain the DDCt values. Finally, sample mRNA
abundance relative to control mRNA abundance was calculated
by the formula 2
2(DDCt).
Statistics
Statistical analysis was performed using SPSS version 17.0
(SPSS inc., Chicago, IL, USA). Data are presented as median
values 6 interquartile range. Comparisons between groups were
performed using the nonparametric Kruskal-Wallis test for
multiple comparisons and the Mann-Whitney test for two groups.
A p value of less than 0.05 was considered significant.
Results
Patient demographics
21 patients (12 male, 9 female) with a mean age of 68 years were
included in the study. The majority were referred after an episode
of haemoptysis for exclusion of an underlying malignancy. The
mean FEV1 was 1.36 L (54% predicted), FVC 2.69 L and FEV1/
FVC ratio 50.5. None of the patients had taken oral corticosteroids
for at least 8 weeks prior to the study, and no individual had
bronchodilator reversibility of greater than 10%.
Cell culture
Bronchial and nasal epithelial cells obtained by brushings from
each site reached confluence after 10–14 days, with a trend
towards a longer time required for the bronchial epithelial cells.
Cell cultures selected at random confirmed epithelial phenotype of
the cells (Figure 1). The success rate was 80–90% from obtaining
cells to growing to sufficient numbers to facilitate experiments.
Mediator release
Stimulation with P aeruginosa LPS (5–25 mg/ml) elicited a dose
dependent release of IL-8 from both nasal and bronchial epithelial
Nasal and Bronchial Epithelial Cells in COPD
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nasal cells was higher than that secreted by the bronchial cells, the
release was correlated (Figure 2B). IL-6 secretion was less than that
of IL-8, with minimal secretion from the bronchial epithelial
cultures (Figure 3).
Preliminary experiments indicated that the 5% CSE chosen for
the studies did not cause cell death. Higher concentrations than
5% CSE caused unacceptable cytotoxicity for both bronchial and
nasal epithelial cells (Figure S1A). A 4 h preincubation with CSE
inhibited basal IL-8 release from both nasal and bronchial cells
(only reaching statistical significance for the bronchial epithelial
cells). However, there was a trend for increased release after a 24 h
preincubation with CSE (5%) for the nasal cells only, inhibiting
release from the bronchial cells (Figure 4A). Incubation with
acrolein for 4 h also gave divergent results, stimulating IL-8 release
from the nasal cells, but having no effect on IL-8 release from
bronchial cells (Figure 4B).
After treating primary bronchial epithelial cells with 25 mg/ml
LPS for 24 h in the ALI culture model there was a 1.29 fold
increase in IL-8 release. This was reduced to 0.53 fold change
relative to control after pre-treatment with CSE for 24 h. The
corresponding values for the submerged model were 2.72 and 1.84
respectively. Control release of IL-8 was 33,449 pg/ml and
893 pg/ml in the ALI and submerged models respectively.
Protein expression of TLR-4 is reduced in bronchial
epithelial cell cultures after treatment with CSE
TLR-4 was predominantly expressed intracellularly in both
nasal (Figure S1B) and bronchial epithelial cells (Figure 5A & 5B),
and therefore cells were permeabilised for all measurements after
Figure 1. Immunocytochemistry for cytokeratin 5 in nasal and bronchial epithelial cell cultures. Primary nasal (A) and bronchial (B)
epithelial cell cultures were stained with a rabbit anti-human antibody against cytokeratin 5 (1:100). The primary antibody was detected using a
secondary antibody coupled to Alexafluor 568 (1:500). Nuclei were stained blue with DAPI (640).
doi:10.1371/journal.pone.0032924.g001
Figure 2. (A) IL-8 dose response and (B) linear regression analysis from paired nasal and bronchial epithelial cells from COPD
subjects after 24 h treatment with LPS. Paired nasal and bronchial epithelial cells were with various concentrations of LPS [5–25 mg/ml] for 24 h
(n=8). Supernatants were collected and assessed for IL-8 by ELISA in all cases. Data are displayed as median (interquartile range). * indicates a
significant difference (p,0.05).
doi:10.1371/journal.pone.0032924.g002
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bronchial epithelial cells were with various concentrations of LPS [0–25 mg/ml] for 24 h (n=8). Supernatants were collected and assessed for IL-6 by
ELISA in all cases. Data are displayed as median (interquartile range). * indicates a significant difference (p,0.05).
doi:10.1371/journal.pone.0032924.g003
Figure 4. Effects of (A) 5% CSE and (B) acrolein on IL-8 release from nasal and bronchial epithelial cultures. Cells were treated 5% CSE
prepared with a single cigarette for 4 h or 24 h (n=5). In separate experiments, cells were treated with increasing concentrations of acrolein for 4 h.
Supernatants were collected and assessed for IL-8 by ELISA in all cases. Data are displayed as median (interquartile range). * indicates a significant
difference (p,0.05).
doi:10.1371/journal.pone.0032924.g004
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TLR-4 was significantly decreased after treatment with CSE for
24 h (Figure 5C), but not after 4 h (Figure S1C). There were no
significant changes in the nasal epithelial cell cultures for either
exposure time (Figure 5D).
mRNA expression of TLR-4
Our results show similar mRNA expression of TLR-4 after
treatment with P aeruginosa LPS, either with or without pre-
treatment with CSE for 4 h or 24 h (Figure 6).
Discussion
These experiments tested the hypothesis that the inflammatory
responses are related in the upper and lower airways. The
responses were monitored by measuring IL-6 and IL-8 release
from cell cultures, under resting and stimulated conditions, as well
as examining TLR-4 message and expression.
The principle of a united airway proposes that clinically the
upper and lower airway mirror each other in terms of their
individual disease manifestations [13]. The use of nasal epithelial
cells in cell culture models as an alternative to bronchial epithelial
cells is dependent on a correlation between their respective
inflammatory responses. In order to address this hypothesis,
McDougall et al., demonstrated that although there was a
significant difference in absolute mediator levels in paired nasal
and bronchial monolayer cell cultures, there was a correlation in
the inflammatory cytokine levels (both basally and after stimula-
tion) [6]. However, their 35 subjects were heterogeneous both in
terms of the age range and the spectrum of underlying lung
pathology. In contrast, a satisfactory correlation was not present
for basal and stimulated mediator release for bronchial and nasal
epithelial cells from asthmatic and non-asthmatic children [7].
Our data extends previous findings using cystic fibrosis
tracheobronchial epithelial cells indicating that IL-8 secretion
was greater than IL-6 secretion (basally and after stimulation) [14].
Figure 5. Representative FACS histograms demonstrating intracellular-location of TLR-4, and a reduced total TLR-4 after CSE
treatment. Localisation of Toll-like receptor 4 (TLR-4). (A): Representative histogram for surface and cytoplasmic staining for IgG and TLR-4 in
bronchial epithelial cells. (B): rMFI for TLR-4 in permeabilised and non-permeabilised nasal and bronchial epithelial cells. (C): Staining for TLR-4 in
permeabilised bronchial epithelial cells after stimulated with 25 mg/ml P aeruginosa LPS, with or without 24 h pre-treatment with CSE. (D): rMFI for
TLR-4 was lower in bronchial epithelial cells than for nasal epithelial cells (for control, 4 h and 24 h CSE treatment). A 24 h exposure to CSE
significantly decreased rMFI for bronchial, but not for nasal, epithelial cells. Data are displayed as median (interquartile range). * indicates a significant
difference (p,0.05).
doi:10.1371/journal.pone.0032924.g005
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bronchial and nasal cell cultures (Figure 2A), the release was
strongly correlated (Figure 2B). In contrast, although there was a
significant IL-6 dose dependent release from the nasal epithelial
cells after stimulation with P aeruginosa LPS, this was not evident in
the bronchial cell cultures (Figure 3). The responses of nasal and
bronchial epithelial cell cultures to treatment with acrolein, an
important constituent of cigarette smoke, were also divergent.
Although the nasal cultures were stimulated by acrolein after a 4 h
incubation period, there was no effect on the bronchial cell
cultures (Figure 4B).
Data on the effects of acrolein in various cell culture models are
inconsistent. Treating nasal epithelial cell cultures (from subjects
with chronic rhinosinusitis) with acrolein suppresses basal IL-8
release [15]. Acrolein has also been reported to stimulate IL-8
release from cultured small airway epithelial cells [16]. Other
groups have indicated that acrolein inhibits IL-8 release in primary
bronchial epithelial cells, and in immortalised bronchial epithelial
cell lines [17]. Similar concentrations of acrolein were used in all of
these studies (5–30 mM range). Thus, although acrolein has
profound effects on epithelial cells, these responses are critically
dependent on the cell type. Overall, these findings emphasise the
importance to study cells from the relevant anatomical location for
any given disease.
The higher IL-8 release from nasal cultures is not particularly
surprising. Nasal epithelial cells have a greater exposure to
respirable inflammatory particles in the environment. Thus, the
upper airway acts to protect the more sensitive lower airways from
infectious agents, allergens and pollutants in the environment.
Devalia el al. provided further evidence to unite the nasal and
bronchial epithelium by comparing bronchial and nasal epithelial
cells acquired from tissue from subjects attending for turbinectomy
and lung surgery respectively, and reported few differences
between the nasal and bronchial cells with respect to their
morphology or ciliary activity [18]. However, the samples were
not obtained from the same individuals. From the published data,
in adults, it appears that nasal epithelial cells can be used as a
satisfactory surrogate for bronchial epithelial cells for many
morphological and functional endpoints. However, we have
shown this is not valid for all situations.
Although we have shown differences in soluble mediator release
from epithelial cells, previous data suggest that there is a conserved
response to cigarette smoke exposure at both sites in terms of
smoking-related gene expression, in particular for those genes
related to oxidative stress and wound healing [19,20]. However, in
a subset of genes, expression was affected more dramatically in the
bronchial than in the nasal epithelium [20]. We found that
exposure to CSE reduced intracellular TLR-4 (Figure 5C), without
modifying mRNA expression (Figure 6).
The localisation of TLR-4 is controversial. There are a number
of studies which indicate that this receptor is present at the cell
surface and that it is functional at this site, whereas other studies
Figure 6. Effect of LPS ±5% CSE pre-treatment on TLR-4 mRNA expression. Nasal epithelial cell cultures were pretreated with 5% CSE
prepared for (A) 4 h,(B) 24 h or vehicle, and subsequently stimulated with P aeruginosa LPS [10–30 mg/ml]for 24 h. Experiments were repeated in
bronchial epithelial cell cultures, again for (C) 4 h and (D) 24 h 5% CSE exposure.
doi:10.1371/journal.pone.0032924.g006
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the activation process of TLR-4 requires internalisation of LPS.
These differences may be explained by the cell type used. A
predominant surface expression was reported in studies using CF
airway cell lines and primary alveolar type 2 cells [21,22], whereas
intracellular expression was found with human bronchial epithelial
cell lines and the A549 alveolar carcinoma epithelial cell line [23].
Our FACS data indicates that in COPD bronchial epithelial cells,
TLR-4 is present both on the surface and intracellularly, although
predominantly in the latter location. Interestingly, a reduced
inflammatory response to stimulation with LPS from Gram-
negative bacteria in cystic fibrosis airway epithelial cells has
previously been attributed to a lower surface expression of surface
TLR-4, a finding which is reflective of our experiments using CSE
[24]. This reduced surface expression of TLR may in fact be an
appropriate response, serving to mitigate damaging inflammation
in the lower airways.
The reported effects of CSE on TLR-4 expression are equally
conflicting. A dose dependent down-regulation of TLR-4 in A549
cells, at both mRNA and protein expression, after stimulation with
CSE has been reported [5]. In contrast, a later publication
suggested that CSE increases TLR-4 expression in BEAS-2B cells
[25]. Similar CSE concentrations were used, but the exposure
time differed with the 4 h exposure causing down-regulation, and
the 18 h causing up-regulation of TLR-4 expression.
All of our experiments are performed on cells at passage 2–3.
These cell cultures require approximately two weeks to become
confluent in T75 flasks during which time the media is changed on
alternate days. The environment both within the nose and the
main airways is therefore unlikely to have any influence on the
phenotype of the cell cultures themselves. The higher soluble
mediator release from the nasal cultures compared to the
bronchial cultures can therefore be attributed to intrinsic
phenotype, rather than attributed to their site of retrieval.
Our results demonstrate that a brief CSE exposure suppresses
the inflammatory response in COPD nasal epithelial cells to
stimulation with LPS, and that a more prolonged CSE exposure
for 24 h heightens the inflammatory response, although neither
response reached statistical significance (Figure 4A). These in vitro
findings suggesting a pro-inflammatory effect of prolonged CSE
exposure in this cell type is reflective of in-vivo research whereby
mice exposed to volatile smoke for 3 days developed a marked
inflammatory cell recruitment in the airways which interestingly
was TLR4 dependent [26]. In contrast, we have demonstrated
that treating primary human bronchial epithelial cells with CSE in
the same experimental conditions was solely immunosuppressive.
These findings are also similar to mice exposed to mainstream
cigarette smoke where a different inflammatory response in the
upper and lower airways was apparent [27]. We adopted 2
exposure times in order to facilitate a comparison of our data with
other published work. The concentrations of CSE used can range
from 100% CSE for 15 minutes [28] to a 1% CSE for 24 hours (in
those studies which use a single cigarette to prepare the initial
‘‘100%’’ stock CSE) [29]. A study exposing primary human nasal
epithelial cells to CSE for 1 h, 2 h, and 4 h reported a time and
dose-dependent cytotoxicity of CSE [30].
The methods used in CSE research are strikingly diverse which
may account for the conflicting reports whether CSE has pro-
inflammatory effects [28,31]. Different cigarettes ranging from the
international reference cigarette KY1R3F [32] to popular brands
of cigarettes are used [33]. In some cases, the particular type of
cigarette has not been defined [34]. In one study, the cigarettes
used did not have a filter [35], whereas in others the filter was
manually removed [12,32]. The presence of a filter actually
increases the production of tar phase and stable free radicals that
are present in mainstream cigarette smoke [36]. In the majority of
studies, cigarette smoke is bubbled through tissue culture medium
without serum [33,37], or alternatively phosphate buffered saline
was used as the diluent [32]. The lack of consensus in terms of the
inherent capacity for CSE to induce a pro-inflammatory response
in epithelial cells may be attributable to an absence of broadly
accepted standardised protocol for the collection and processing of
cigarette smoke.
Submerged cell culture models are most widely used in CSE
research [28,29,38,39,40,41]. However, ALI cultures have become
increasingly popular particular when morphological endpoints are
evaluated [42], These cell cultures form many layers, and after 2
weeks in culture develop beating cilia and goblet cells. We have
successfully cultured bronchial epithelial cells in this model (in
conjunction with submerged cultures) and proceeded to compare
responses after stimulation with 25 mg/ml LPS, with or without
CSE pre-treatment for 24 h. Although both cultures were
stimulated with LPS, this was more pronounced in the submerged
model. A limitation of the technique we use to obtain primary
bronchial epithelial cells is the relatively low yield of cells obtained
in comparison to those groups who obtain cells from transplanted
lungs [14]. This limits the number of experiments that we can
perform.
In conclusion, our data indicate that although nasal epithelial
cells can be used as suitable surrogates for bronchial epithelial cells
for IL-8 responses to P aeruginosa LPS, but not for IL-6 release,
responses to CSE, acrolein, or TLR-4 expression. The combina-
tion of a relatively non-invasive and inexpensive nasal brushing
procedure facilitates a unique opportunity to study the specific
patterns of inflammatory responses in a number of settings, but
nasal epithelial cell responses cannot be extrapolated to those of
the lower airway in subjects with COPD when these particular
endpoints are considered. Investigating cytokine protein panels or
microarray analysis would serve to extend these findings in a
broader context.
Supporting Information
Figure S1 Localisation of Toll-like receptor 4 (TLR-4).
(A) CSE dose dependent cytotoxicity for nasal and bronchial
epithelial cells determined using the 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide (MTT) assay. (B) Representative
histogram for surface and cytoplasmic staining for IgG and TLR-4
in nasal epithelial cells. (C) TLR-4 expression in PBECs after 4 h
and 24 h CSE exposure, both prior to LPS stimulation.
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